EU Approval of Keytruda‑Padcev Boosts Merck’s Oncology Sales — What It Means for Cancer‑Drug Portfolios
Merck’s new bladder‑cancer combo clears the EU, unlocking a $2 billion revenue runway and reshaping oncology exposure across biotech and pharma stocks.